ArticleOrphanet journal of rare diseases2025
Clinicopathological-genetic features of neutral lipid storage disease with myopathy from a Chinese neuromuscular center.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Delving into the clinical and genetic spectrum of NLSDM: A case study.Journal of neuromuscular diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundNeutral lipid storage disease with myopathy (NLSDM) is a rare genetic myopathy caused by mutations in the patatin-like phospholipase domain-containing protein (PNPLA2) gene. To date, the number of reported cases remains limited and the correlation between disease phenotypes and genotypes remains unclear.
resultsOur study presents eight NLSDM patients from a Chinese neuromuscular center, identifying two PNPLA2 novel mutations through next-generation sequencing. Demographic and clinical data, as well as information from muscle electrophysiological, imaging, pathological, and genetic analyses, were collected. Several patients in the cohort were found to have right upper extremity weakness as the initial clinical manifestation. Notably, the first patient with facial muscle involvement was reported in this series. Muscle histopathology revealed a characteristic accumulation of lipid droplets predominantly in type 1 muscle fibers, featuring type 1 fiber atrophy concurrent with type 2 fiber hypertrophy, which was systematically described first in a summary manner.
conclusionsThis study prompted us to summarize abnormal clinicopathological features and explore the relationship between gene mutations and disease phenotypes in NLSDM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.